发明名称 |
HMG-CoA reductase inhibitor extended release formulation |
摘要 |
Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (T<SUB>max</SUB>) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.
|
申请公布号 |
US2006141036(A1) |
申请公布日期 |
2006.06.29 |
申请号 |
US20060355771 |
申请日期 |
2006.02.16 |
申请人 |
|
发明人 |
CHEN CHIH-MING;CHOU JOSEPH;WONG DAVID |
分类号 |
A61K9/22;A61K9/00;A61K9/20;A61K9/28;A61K31/22;A61K31/366 |
主分类号 |
A61K9/22 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|